FLT-PET as an Imaging Biomarker With Temsirolimus, Topotecan, and Bortezomib
NCT01143779
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
3
Enrollment
OTHER
Sponsor class
Conditions
Advanced Cancer
Interventions
DRUG:
FLT-PET
Sponsor
M.D. Anderson Cancer Center